NLRP3 and breast carcinoma: MiR-223 may suppress the development of breast cancer by targeting multiple oncogenic transcripts (Table 1), including epithelial cell transforming 2 (ECT2), Profilin 2 (PFN2) and NLRP3 [131,132,133].